Histone deacetylase inhibitors as novel neuroprotective agents in in vitro and in vivo models of Parkinson's disease
Histone deacetylases (HDAC) shift the balance towards chromatin condensation and silence gene expression. Aberrant recruitment of HDACs to alter transcription suggests the use of HDAC inhibitors (HDAC-Is) as potential therapeutic candidates for neurodegenerative disorders such as Parkinson’s disease...
| Main Author: | |
|---|---|
| Published: |
King's College London (University of London)
2014
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628485 |